Biostax Corp. (BTAX) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBiostax Corp. (BTAX) trades at $0.0002. Biostax Corp. is a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products, including its lead drug candidate Lodonal for HIV/AIDS. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for BTAX: BTAX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BTAX against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
BTAX: 1/2 scored disciplines lean bullish. Dominant signal: Izzy Englander bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Biostax Corp. (BTAX) Healthcare & Pipeline Overview
Biostax Corp., formerly Immune Therapeutics, is a biopharmaceutical company developing Lodonal for HIV/AIDS and exploring telehealth and blockchain applications in healthcare. Operating in the biotechnology sector, the company focuses on acquiring and commercializing pharmaceutical products, facing competition from established and emerging players while navigating regulatory and funding challenges.
What Is the Investment Thesis for BTAX?
Biostax Corp. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The primary value driver is the successful development and commercialization of Lodonal for HIV/AIDS, a market with ongoing medical needs. Further potential lies in the development of JKB-122 for liver diseases like NAFLD and NASH. Growth catalysts include positive clinical trial results for Lodonal and JKB-122, strategic partnerships, and successful navigation of regulatory hurdles. However, the company faces significant risks, including the need for additional funding, potential clinical trial failures, and competition from established pharmaceutical companies. The company's market capitalization is $0.00B, reflecting the speculative nature of its pipeline and early-stage development programs.
Based on FMP financials and quantitative analysis
BTAX Key Highlights
Biostax Corp.'s lead drug candidate, Lodonal, targets the HIV/AIDS market, representing a significant unmet medical need.
- The company is exploring blockchain technology for healthcare applications, potentially creating new revenue streams and competitive advantages.
- Biostax Corp. has a licensing agreement with Cytocom Inc., potentially providing access to additional technologies and expertise.
- The company's pipeline includes JKB-122, targeting autoimmune hepatitis, NAFLD, and NASH, addressing a growing market with limited treatment options.
- Biostax Corp. changed its name from Immune Therapeutics, Inc. in October 2023, signaling a potential shift in strategy or focus.
Who Are BTAX's Competitors?
BTAX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| HSTC HST Global, Inc. | $0.65 | 0.00% | $91.9M | — |
| NVO Novo Nordisk A/S | $44.01 | -1.23% | $195B | 925-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $514.90 | +0.07% | $131B | 965-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
| ARGX argenx SE | $984.04 | -1.82% | $61.2B | 975-pillar |
| UCBJY UCB S.A. | $117.06 | -1.42% | $44.6B | 679-signal |
| ALNY Alnylam Pharmaceuticals, Inc. | $247.51 | -4.07% | $33.1B | 895-pillar |
| RPRX Royalty Pharma plc | $58.75 | -3.04% | $26.0B | 725-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are BTAX's Key Strengths?
Diverse pipeline of pharmaceutical and biotechnology products.
- Focus on unmet medical needs.
- Potential for breakthrough therapies.
- Exploration of innovative technologies like blockchain and telehealth.
What Are BTAX's Weaknesses?
Limited financial resources.
- Early-stage development programs.
- Dependence on successful clinical trials.
- Lack of established commercial infrastructure.
What Could Drive BTAX Stock Higher?
Clinical trial results for Lodonal in HIV/AIDS patients.
- Regulatory submissions for JKB-122 for autoimmune hepatitis, NAFLD, and NASH.
- Development and launch of the Global Telehealth platform.
- Progress in the Medtech asset development using blockchain technology.
- Exploration of Low Dose Naltrexone applications and clinical trials.
What Are the Key Risks for BTAX?
Clinical trial failures for Lodonal or JKB-122.
- Regulatory delays or rejections.
- Competition from established pharmaceutical companies.
- Need for additional funding to support operations and development.
- Dependence on key personnel and strategic partnerships.
What Are the Growth Opportunities for BTAX?
- Lodonal Development and Commercialization: The successful development and commercialization of Lodonal for HIV/AIDS represents a significant growth opportunity for Biostax. The global HIV/AIDS market is expected to continue to grow, driven by increasing prevalence and the need for improved therapies. If Lodonal demonstrates superior efficacy and safety compared to existing treatments, it could capture a significant share of the market. The timeline for this growth opportunity depends on the successful completion of clinical trials and regulatory approval, potentially within the next 3-5 years.
- JKB-122 for Liver Diseases: The development of JKB-122 for autoimmune hepatitis, NAFLD, and NASH represents another significant growth opportunity. These liver diseases are becoming increasingly prevalent, driven by factors such as obesity and diabetes. There is a significant unmet need for effective therapies, and JKB-122, as a TLR4 antagonist, has the potential to address this need. The timeline for this growth opportunity depends on the successful completion of clinical trials and regulatory approval, potentially within the next 4-6 years.
- Global Telehealth Platform: Biostax's development of a Global Telehealth platform offers a growth opportunity in the expanding telehealth market. The telehealth market is experiencing rapid growth, driven by increasing demand for remote healthcare services and technological advancements. By providing a comprehensive telehealth platform, Biostax can potentially capture a share of this growing market. The timeline for this growth opportunity depends on the successful development and launch of the platform, potentially within the next 2-3 years.
- Medtech Asset with Blockchain Technology: The development of a Medtech asset using blockchain and smart contracts for managing prescriptions and electronic health records presents a novel growth opportunity. Blockchain technology offers the potential to improve the security and efficiency of healthcare data management. By leveraging blockchain, Biostax can potentially create a competitive advantage in the Medtech market. The timeline for this growth opportunity depends on the successful development and implementation of the blockchain-based system, potentially within the next 3-4 years.
- Low Dose Naltrexone (LDN) Applications: Exploring the potential of Low Dose Naltrexone (LDN) for immune-modulating benefits in areas like cancer, pain, autoimmune disorders, and anti-aging opens up diverse growth avenues. While the scientific evidence for LDN's efficacy in these areas is still evolving, positive clinical data could lead to significant market opportunities. The timeline for this growth opportunity is dependent on further research and clinical trials, potentially yielding results within the next 3-5 years.
What Opportunities Does BTAX Have?
- Strategic partnerships with larger pharmaceutical companies.
- Out-licensing of developed products.
- Expansion into new therapeutic areas.
- Acquisition of complementary technologies or assets.
What Are BTAX's Competitive Advantages?
- Patent protection for developed pharmaceutical products.
- Proprietary formulations and drug delivery systems.
- Strategic partnerships and licensing agreements.
- First-mover advantage in specific therapeutic areas or technologies.
What Does BTAX Do?
Biostax Corp., formerly known as Immune Therapeutics, Inc., was rebranded in October 2023 and operates as a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products. The company's lead investigational drug candidate is Lodonal, an oral, once-a-day immune system regulator being developed for the management of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS). Beyond Lodonal, Biostax is also pursuing a Global Telehealth platform, aiming to provide remote healthcare solutions. The company is also developing a Medtech asset, an early-stage program leveraging blockchain and smart contracts to manage and secure prescriptions and electronic health records. Another key asset is JKB-122, an investigational small molecule, long-acting toll-like receptor 4 (TLR4) antagonist being developed for autoimmune hepatitis, nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). Additionally, Biostax is exploring Low Dose Naltrexone, a compound formula purported to provide immune-modulating benefits for conditions including cancer, pain, autoimmune disorders, and anti-aging. The company also has programs for the treatment of hyperphosphatemia. Biostax has a licensing agreement with Cytocom Inc. and is headquartered in Winter Park, Florida.
What Products and Services Does BTAX Offer?
- Acquires pharmaceutical and biotechnology products.
- Develops pharmaceutical products, including Lodonal for HIV/AIDS.
- Commercializes pharmaceutical products.
- Develops a Global Telehealth platform for remote healthcare.
- Develops a Medtech asset using blockchain for secure prescription management.
- Develops JKB-122 for autoimmune hepatitis, NAFLD, and NASH.
- Explores Low Dose Naltrexone for immune-modulating benefits.
- Develops programs for the treatment of hyperphosphatemia.
How Does BTAX Make Money?
- Develops and patents pharmaceutical products.
- Out-licenses or partners for commercialization of developed products.
- Acquires rights to existing pharmaceutical products.
- Generates revenue through product sales, licensing fees, and milestone payments.
What Industry Does BTAX Operate In?
Biostax Corp. operates in the highly competitive biotechnology industry, characterized by intense research and development, lengthy regulatory approval processes, and significant capital requirements. The industry is driven by innovation and the development of new therapies for unmet medical needs. Key trends include the rise of personalized medicine, the increasing use of data analytics and artificial intelligence, and the growing importance of strategic partnerships. Biostax competes with both large pharmaceutical companies and smaller biotech firms, including companies developing therapies for HIV/AIDS, liver diseases, and other conditions. The company's success depends on its ability to develop and commercialize innovative products, secure funding, and navigate the complex regulatory landscape.
Who Are BTAX's Key Customers?
- Patients with HIV/AIDS (Lodonal).
- Patients with autoimmune hepatitis, NAFLD, and NASH (JKB-122).
- Healthcare providers using the Global Telehealth platform.
- Pharmacies and healthcare organizations using the Medtech asset.
- Patients seeking immune-modulating benefits (Low Dose Naltrexone).
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 47 |
| 2026-08-26 | 47 |
| 2026-08-29 | 47 |
| 2026-09-01 | 47 |
| 2026-09-04 | 47 |
| 2026-09-07 | 47 |
| 2026-09-10 | 47 |
What changed?
The score has stayed at 47.
Over the same 18 days the stock moved +0.0%.
Key Financial Metrics
Return on equity for Biostax Corp. stands at 67.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Biostax Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Winter Park, US. The company is led by CEO Noreen Griffin. BTAX has traded publicly since 2010.
BTAX Financials
Bull Case vs Bear Case
Bull Case
- Diverse pipeline of pharmaceutical and biotechnology products.
- Focus on unmet medical needs.
- Potential for breakthrough therapies.
- Exploration of innovative technologies like blockchain and telehealth.
Bear Case
- Limited financial resources.
- Early-stage development programs.
- Dependence on successful clinical trials.
- Lack of established commercial infrastructure.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BTAX Latest News
No recent news available for BTAX.
BTAX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BTAX.
Price Targets
Wall Street price target analysis for BTAX.
BTAX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BTAX; grades run from A+ (80-100) to F (below 30).
Leadership: Noreen Griffin
CEO
Noreen Griffin is the CEO of Biostax Corp. Her background includes extensive experience in the pharmaceutical and biotechnology industries. She has held leadership positions in various companies, focusing on strategic planning, business development, and commercialization. Griffin's expertise spans across multiple therapeutic areas, including infectious diseases and autoimmune disorders. She has a proven track record of driving growth and creating value for shareholders.
Track Record: Since becoming CEO, Noreen Griffin has focused on restructuring Biostax Corp. and advancing its pipeline of pharmaceutical and biotechnology products. Key milestones include the rebranding of the company from Immune Therapeutics, Inc. to Biostax Corp. and the continued development of Lodonal for HIV/AIDS. She has also overseen the exploration of new technologies like blockchain and telehealth.
BTAX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biostax Corp. may not meet the minimum financial or disclosure requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, lower trading volume, and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the potential for less stringent listing standards and reduced transparency.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Potential for wider bid-ask spreads.
- Increased risk of fraud or manipulation.
- Higher volatility compared to exchange-listed stocks.
- Verify the company's registration and compliance with SEC regulations.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with the company's industry and operations.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Experienced management team with relevant industry expertise.
- Clear business plan and strategy.
- Partnerships or collaborations with reputable organizations.
- Intellectual property protection (patents, trademarks).
- Positive news coverage or industry recognition.
What Investors Ask About Biostax Corp. (BTAX) — Healthcare
Is BTAX a good stock?
Stock Expert AI does not rate BTAX buy, sell or hold. Biostax Corp. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for BTAX?
The main risks for Biostax Corp. include the potential for clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.
What are the key factors to evaluate for BTAX?
Evaluate BTAX on fundamentals, analyst consensus, and risk factors. Further potential lies in the development of JKB-122 for liver diseases like NAFLD and NASH. Not financial advice.
How frequently does BTAX data refresh on this page?
BTAX's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BTAX's recent stock price performance?
Biostax Corp. (BTAX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse pipeline of pharmaceutical and biotechnology products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BTAX overvalued or undervalued right now?
Biostax Corp. (BTAX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BTAX?
Yes, most major brokerages offer fractional shares of Biostax Corp. (BTAX) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BTAX's earnings and financial reports?
Biostax Corp. (BTAX) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BTAX earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or unreliable.